Advanced search    

Search: authors:"Evo Alemao"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). Adjusted mean changes from baseline to weeks 16 (all patients) and 24 (non-EE responders) in Health Assessment...

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis

association of HAQ change by baseline DAS categories. (DOCX) Author Contributions Formal analysis: Evo Alemao. Methodology: Evo Alemao. Conceptualization: Evo Alemao, Maiwenn J. Al, Maureen P. M. H. Rutten ... . Writing ± original draft: Evo Alemao. Writing ± review & editing: Maiwenn J. Al, Annelies A. Boonen, Matthew D. Stevenson, Suzanne M. M. Verstappen, Kaleb Michaud, Michael E. Weinblatt, Maureen P. M. H

Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort

assistance was provided by Stacey Reeber, PhD, at Caudex and was funded by Bristol-Myers Squibb. Disclosures. Harris A. Ahmad is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Evo ... Alemao is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Zhenchao Guo is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Michael Weinblatt has

Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept

France; consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, UCB; board member: Executive Committee of OMERACT. Souhila Ahdjoudj: employee: Bristol-Myers Squibb. Evo ... Alemao: shareholder and employee: Bristol-Myers Squibb. Vibeke Strand: consulting fees: AbbVie, Alder, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Celltrion, Corrona, Crescendo Bioscience, Genentech

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona RA registry (February 2006–January 2015), biologic-naïve patients with RA initiating abatacept with 12-month (±3 months) follow-up and assessment of...